The Melanoma Letter Fall 2011, Vol. 29, No. 2

In this issue of The Melanoma Letter, Dr. Paul Chapman discusses the exciting, newly FDA-approved drug ZelborafTM (vemurafenib), which targets a unique mutation in the BRAF gene that is remarkably common among patients with advanced melanoma. The striking responses of many patients to this drug serve as a beacon of hope that someday treatments will become available that will truly eliminate advanced melanomas and lead to genuine ‘cures’.

Research is already under way to determine whether combining BRAF inhibitors with other therapies such as ipilimumab (YervoyTM) may offer therapeutic benefit to more patients afflicted with melanoma.